Corgenix to Exhibit AspirinWorks(R) Test at 2008 ACOFP Meeting in Denver.
DENVER, March 7 /PRNewswire-FirstCall/ -- Corgenix Medical Corporation (BULLETIN BOARD: CONX) , a worldwide developer and marketer of diagnostic test kits, will be exhibiting its AspirinWorks(R) Test at the American College of Family Physicians 45th Annual Convention & Exhibition. ACOFP ACOFP American College of Osteopathic Family Physicians 2008 conference is being held March 12-14 at the Colorado Convention Center in Denver.
Corgenix representatives will be on-hand at booth #807 during ACOFP to answer questions about the AspirinWorks test, including its availability, the latest supporting clinical data and ordering information.
AspirinWorks is a simple urine test that determines the effect of aspirin on platelets by measuring the level of thromboxane thromboxane /throm·box·ane/ (-bok´san) either of two compounds, one designated A2 and the other B2. Thromboxane A2 is synthesized by platelets and is an inducer of platelet aggregation and platelet release functions and is a production (aspirin's target). The higher the levels of thromboxane, the stickier the blood platelets, and the less impact the aspirin is having. This crucial information allows physicians to individualize a patient's therapy.
Unlike other platelet tests, which require freshly drawn blood that must be evaluated within four hours, the AspirinWorks test only requires a urine sample that can be obtained in any doctor's office or patient service center, making the test easy for both physician and patient.
"The ACOFP conference represents a special opportunity to reach this medical specialty medical specialty Any specialty that provides non-interventional Pt management, ie with drugs, or with minimum intervention–eg, balloon catheterization Examples Internal medicine–allergy and immunology, cardiology, gastroenterology, hematology/oncology, ," said Corgenix' Clinical Affairs Director Gordon Ens. "With their awareness of the differences among individual patients, we're confident attendees will appreciate the ability to identify individual response to aspirin."
The AspirinWorks Test, which was launched in the United States in June 2007 following FDA 510(k) clearance, is now available nationwide through major medical reference laboratories, as well as direct to consumers through HealthCheckUSA (http://www.healthcheckusa.com/).
The AspirinWorks Test Kit is an enzyme-linked immunoassay Immunoassay
An assay that quantifies antigen or antibody by immunochemical means. The antigen can be a relatively simple substance such as a drug, or a complex one such as a protein or a virus. (ELISA ELISA (e-li´sah) Enzyme-Linked Immuno-Sorbent Assay; any enzyme immunoassay using an enzyme-labeled immunoreactant and an immunosorbent.
n. ) to determine levels of 11 Dehydro Thromboxane B2 (11dhTxB2) in human urine, which aids in the qualitative detection of aspirin effect in apparently healthy individuals post ingestion ingestion /in·ges·tion/ (-chun) the taking of food, drugs, etc., into the body by mouth.
1. The act of taking food and drink into the body by the mouth.
2. . The test targets a potential U.S. market of over 60 million individuals and a potential global market exceeding 200 million individuals who take aspirin regularly.
Physicians and laboratories interested in ordering the test can call 1-800-729-5661 x180, or e-mail: firstname.lastname@example.org. More information is also available at http://www.aspirinworks.com/.
It is important that individuals taking aspirin to lower the risk of a heart attack or stroke consult a physician to determine what dose, frequency and type of aspirin is appropriate for them to achieve the most benefit with the fewest side effects.
About Corgenix Medical Corporation
Corgenix is a leader in the development and manufacturing of specialized diagnostic kits for immunology disorders, vascular diseases and bone and joint disorders. Corgenix diagnostic products are commercialized for use in clinical laboratories throughout the world. The company currently sells over 50 diagnostic products through a global distribution network. More information is available at http://www.corgenix.com/.
Statements in this press release that are not strictly historical facts are "forward-looking" statements (identified by the words "believe", "estimate", "project", "expect" or similar expressions) within the meaning of the Private Securities Litigation Reform Act The Private Securities Litigation Reform Act of 1995 (PSLRA) implemented several significant substantive changes affecting certain cases brought under the federal securities laws, including changes related to pleading, discovery, liability, class representation and awards fees and of 1995. These statements inherently involve risks and uncertainties that could cause actual results to differ materially from the forward-looking statements. Factors that would cause or contribute to such differences include, but are not limited to, continued acceptance of the Company's products and services in the marketplace, competitive factors, changes in the regulatory environment, and other risks detailed in the Company's periodic report filings with the Securities and Exchange Commission. The statements in this press release are made as of today, based upon information currently known to management, and the Company does not undertake any obligation to publicly update or revise any forward-looking statements.
CONTACT: William Critchfield, Senior VP and CFO See Chief Financial Officer. of Corgenix Medical Corp., +1-303-453-8903, email@example.com; or Media, Dan Snyders, Vice President, Public Relations Supervisor of Armada Medical Marketing, +1-303-623-1190, ext. 230, Fax, +1-303-623-1191, firstname.lastname@example.org, for Corgenix Medical Corporation
Web site: http://www.corgenix.com/ http://www.aspirinworks.com/ http://www.healthcheckusa.com/